AKT1 and breast cancer: Importantly, glutathione biosynthesis has been shown to be a metabolic vulnerability in PIK3CA mutant breast cancer cells, as treatment of PIK3CA or AKT mutant MCF10A cells with buthionine sulfoximine (BSO) significantly reduces anchorage-independent growth and inhibits cell proliferation in 3D, but not 2D culture (83).